Second Alzheimer’s Drug in Pipeline Can Slow the Disease by a Few Months but With Safety Risk

July 17, 2023

(Associated Press) – Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday. Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab. If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease — after the recently approved Leqembi from Japanese drugmaker Eisai. (Read More)